相关实验视频

Updated: Jul 27, 2025

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

在接受多塞塔克塞尔治疗的转移性割耐性前列腺癌患者中,随着时间的推移,有条件生存率没有改善

Daniele Modonutti^1,2, Sami E Majdalany^1,3, Mohit Butaney^1,3

¹Department of Urology, Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation (VCORE), Vattikuti Urology Institute, Henry Ford Health System, Detroit, Michigan, USA.

|June 8, 2023

概括

对于接受多塞塔克塞尔化疗的转移性割抵抗性前列腺癌患者来说,他们的生存机会越长越长. 这一发现有助于个性化后续护理和治疗策略.

科学领域:

在瘤学瘤学.
临床试验临床试验
前列腺癌研究研究前列腺癌

背景情况:

转移性割抵抗性前列腺癌 (mCRPC) 是前列腺癌的晚期阶段.
多塞塔克塞尔化疗是对mCRPC的标准治疗方法.
在接受化疗的mCRPC患者中预测长期生存对于治疗规划至关重要.

研究的目的:

为了研究接受多塞素化疗的转移性割抵抗性前列腺癌 (mCRPC) 患者的条件整体存活率 (OS).
分析在接受多塞塔克塞尔治疗的mCRPC患者的生存概率随着时间的推移而变化.

主要方法:

利用了前列腺癌DREAM挑战和ENTHUSE 14试验中的非身份化患者数据.
包括来自五项随机临床试验的2158名化疗前的mCRPC患者.
在不同时间点 (0,6,12,18,24个月) 计算了6个月的条件OS,并使用验证的名录图分层患者到低风险和高风险组.

主要成果:

在0,6,12,18和24个月的整个队列中,6个月的条件OS率分别为93%,82%,76%,75%,和71%.
与高风险患者相比,低风险患者在所有时间点都始终显示出更高的条件生存率.
随着时间的推移,条件生存率往往会趋于平稳,特别是在治疗的第一年后.

结论:

接受多塞塔克塞尔化疗的mCRPC患者的条件整体存活率显示,随着时间的推移,平原效应.
随着治疗开始后生存时间的延长,进一步生存的可能性会增加.
这些预后信息可以指导更准确地定制随访时间表和治疗干预措施,以实现个性化医疗.

关键词:

雌激素独立的前列腺癌预后预后预后前列腺癌是前列腺癌.

更多相关视频

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...